Impact of the LDL subfraction phenotype on Lp-PLA2 distribution, LDL modification and HDL composition in type 2 diabetes
Por:
Sanchez-Quesada, JL, Vinagre, I, De Juan-Franco, E, Sanchez-Hernandez, J, Bonet-Marques, R, Blanco-Vaca, F, Ordonez-Llanos, J, Perez, A
Publicada:
5 ago 2013
Resumen:
Background: Qualitative alterations of lipoproteins underlie the high incidence of atherosclerosis in diabetes. The objective of this study was to assess the impact of low-density lipoprotein (LDL) subfraction phenotype on the qualitative characteristics of LDL and high-density lipoprotein (HDL) in patients with type 2 diabetes.
Methods: One hundred twenty two patients with type 2 diabetes in poor glycemic control and 54 healthy subjects were included in the study. Patients were classified according to their LDL subfraction phenotype. Seventy-seven patients presented phenotype A whereas 45 had phenotype B. All control subjects showed phenotype A. Several forms of modified LDL, HDL composition and the activity and distribution of lipoprotein-associated phospholipase A2 (Lp-PLA2) were analyzed.
Results: Oxidized LDL, glycated LDL and electronegative LDL were increased in both groups of patients compared with the control group. Patients with phenotype B had increased oxidized LDL and glycated LDL concentration than patients with phenotype A. HDL composition was abnormal in patients with diabetes, being these abnormalities more marked in patients with phenotype B. Total Lp-PLA2 activity was higher in phenotype B than in phenotype A or in control subjects. The distribution of Lp-PLA2 between HDL and apoB-containing lipoproteins differed in patients with phenotype A and phenotype B, with higher activity associated to apoB-containing lipoproteins in the latter.
Conclusions: The presence of LDL subfraction phenotype B is associated with increased oxidized LDL, glycated LDL and Lp-PLA2 activity associated to apoB-containing lipoproteins, as well as with abnormal HDL composition.
Filiaciones:
Sanchez-Quesada, JL:
Biomed Res Inst IIB St Pau, Cardiovasc Biochem Grp, Barcelona 08025, Spain
Vinagre, I:
Hosp Santa Creu & Sant Pau, Endocrinol & Nutr Dept, Barcelona 08041, Spain
De Juan-Franco, E:
Biomed Res Inst IIB St Pau, Cardiovasc Biochem Grp, Barcelona 08025, Spain
Sanchez-Hernandez, J:
CIBER Study Diabet & Associated Metab Dis CIBERDE, Barcelona, Spain
Bonet-Marques, R:
Biomed Res Inst IIB St Pau, Cardiovasc Biochem Grp, Barcelona 08025, Spain
Blanco-Vaca, F:
CIBER Study Diabet & Associated Metab Dis CIBERDE, Barcelona, Spain
Biomed Res Inst IIB St Pau, Metab Factors Cardiovasc Risk Grp, Barcelona 08025, Spain
Univ Autonoma Barcelona, Dept Biochem & Mol Biol, Cerdanyola Del Valles, Spain
Ordonez-Llanos, J:
Biomed Res Inst IIB St Pau, Cardiovasc Biochem Grp, Barcelona 08025, Spain
Univ Autonoma Barcelona, Dept Biochem & Mol Biol, Cerdanyola Del Valles, Spain
Perez, A:
Hosp Santa Creu & Sant Pau, Endocrinol & Nutr Dept, Barcelona 08041, Spain
CIBER Study Diabet & Associated Metab Dis CIBERDE, Barcelona, Spain
Gold, Green Published
|